Drugs and Valvular Heart Disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In 1997, Connolly et al. reported that both racemic fenfluramine (Pondimin) and dexfenfluramine (Redux) were associated with valvular heart disease.1 The valvular abnormalities seen in patients treated with these agents were distinctive. On echocardiography, leaflet thickening as well as chordal thickening and retraction were observed. Surgically removed valves were noted to have a glistening white surface, with histologic evidence of a plaque-like process extending along the leaflet surfaces and encasing the chordae tendineae. These findings were similar to those in patients with heart-valve damage induced by serotonin-secreting carcinoid tumors.1 This association of racemic fenfluramine and dexfenfluramine with valvular heart disease . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, valvular heart disease is associated with anorectic agents, such as fenfluramine, and antimigraine medications, such as ergot-amine, via serotonin 5-HT2B receptor agonism66.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [66]
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1223 · Cited by 304
Self-citationAppetite Suppressants and Valvular Heart Disease
Devereux, R. B. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391109 · Cited by 53
Setola, V., & Roth, B. L. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.377 · Cited by 48
Self-citation
Cited by
Items 301–400 of 503
Whole proteome mapping of compound-protein interactions
Chirasani, V. R., Wang, J., Sha, C. M., Raup‐Konsavage, W. M., Vrana, K. E., & Dokholyan, N. V. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100035 · Cited by 11
“The interaction of drugs with unintended targets (off-targets) may generate adverse drug reactions (Bowes et al., 2012; Campillos et al., 2008; Roth, 2007), such as the severe side effects induced by the fatty acid amide hydrolase (FAAH) inhibitor BIA 10–2474 in a recent clinical trial (Hayes et…”
BackgroundNovel Medical Therapies for Pulmonary Arterial Hypertension
O’Connell, C., O’Callaghan, D. S., & Humbert, M. J. C. (2013) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.08.002 · Cited by 13
Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options
Andrew, C. A., Saunders, K. H., Shukla, A. P., & Aronne, L. J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561867 · Cited by 11
“a serotonin agonist, was found to have off-target effects, stimulating 5-HT2B receptors on cardiac valves leading to the development of valvulopathy [10].”
BackgroundRuffoli, R., Soldani, P., Pasquali, L., Ruggieri, S. A., Paparelli, A., & Fornai, F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1432.017 · Cited by 11
McConnachie, L. A., Goadsby, P. J., Vann, R. E., Ray, S., Shrewsbury, S. B., & Aurora, S. K. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1282846 · Cited by 10
“Agonism at the 5-HT 2B receptor has been implicated in drug-induced valvular heart disease (78).”
BackgroundSelective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines
Green, M. P., McMurray, G., & Storer, R. I. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.06.060 · Cited by 10
GPCR profiling: from hits to leads and from genotype to phenotype
Cvijic, M. E., Sum, C. S., Alt, A. J., & Zhang, L. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.10.005 · Cited by 10
The Safety and Efficacy of Lorcaserin in the Management of Obesity
Hess, R., & Cross, L. B. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.11.2713 · Cited by 12
Capulli, A. K., MacQueen, L. A., O’Connor, B. B., Dauth, S., & Parker, K. K. (2016) · Cardiovascular Pathology · doi:10.1016/j.carpath.2016.04.004 · Cited by 10
“Ergoline-derived medications appear to be especially problematic as a number of anorectics [7] and Parkinson's disease drugs [9] of this class cause fibrosis and gross structural changes to the cardiac valves, similar to the symptoms of carcinoid syndrome [7,8].”
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
Hurt, R. T., Mundi, M. S., & Ebbert, J. O. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s126855 · Cited by 10
“Previously approved medications in this class (fenfluramine and dexfenfluramine) were removed from the market due to association with valvular heart disease likely due to agonist activity of the 5HT 2B receptors, which have increased expression in cardiac tissue.(21,22) Unlike these earlier 5HT medications, lorcaserin…”
BackgroundChowdhury, M. A., Taleb, M., Kakroo, M. A., & Tinkel, J. L. (2014) · Echocardiography · doi:10.1111/echo.12671 · Cited by 9
Dopamine agonist therapy and cardiac valve dysfunction
Sherlock, M., Steeds, R. P., & Toogood, A. A. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02974.x · Cited by 9
Vearrier, D., & Greenberg, M. I. (2017) · Clinical Toxicology · doi:10.1080/15563650.2017.1334913 · Cited by 8
“During the 1990s, numerous lawsuits were filed against manufacturers and distributors of the weight loss drugs fenfluramine and phentermine (fenphen), as well as against the physicians, pharmacies, and weight-loss clinics providing these drugs, after a causal association with valvular heart disease was established [21…”
BackgroundHalberstadt, A. L., Brandt, S. D., Walther, D. M., & Baumann, M. H. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05207-1 · Cited by 8
“5-HT2B activation has been linked to valvular heart disease induced by fenfluramine and ergot alkaloids such as methysergide, pergolide, cabergoline, and ergotamine (Fitzgerald et al. 2000; Rothman et al. 2000; Roth 2007; Huang et al. 2009).”
Orally Inhaled Dihydroergotamine: Reviving and Improving A Classic
Baron, E. P., & Tepper, S. J. (2011) · Future Neurology · doi:10.2217/fnl.11.24 · Cited by 8
Impossible or Merely Difficult? Two Grand Challenges from a Biologist’s Perspective
Roth, B. L. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000386 · Cited by 8
Self-citationDopamine Agonists and Valvular Heart Disease
Stephens, J. W., Price, D. E., & Ionescu, A. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070227 · Cited by 10
Preclinical mitigation of 5-HT2B agonism-related cardiac valvulopathy revisited
Dumotier, B. M., & Urbán, L. (2024) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2024.107542 · Cited by 11
Artificial Intelligence in Cardiovascular Diseases
Bashir, S., Ahanger, A. N., Assad, A., Bhat, M. R., & Macha, M. A. (2025) · Springer eBooks · doi:10.1007/978-981-96-8176-1_10 · Cited by 11
RESULTS OF 5-YEAR OBSERVATION FOR PATIENTS WITH HEART DISEASE
Petrov, V. S. (2015) · I P Pavlov Russian Medical Biological Herald · doi:10.17816/pavlovj2015383-87 · Cited by 7
Surgery as a first-line option for prolactinomas
Mamelak, A. N. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2131531 · Cited by 7
“Valvular heart disease arising from chronic DA use has also been reported [80,81].”
BackgroundGillam, M. P., & Molitch, M. E. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380926-1.10015-x · Cited by 13
Lapi, F., Nicotra, F., Scotti, L., Vannacci, A., Thompson, M., Pieri, F., Mugelli, N., Zambon, A., Corrao, G., Mugelli, A., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04224.x · Cited by 7
Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT2C agonists
Andrews, M. D., Green, M. P., Allerton, C. M. N., Batchelor, D. V., Blagg, J., Brown, A. D., Gordon, D. W., McMurray, G., Millns, D. J., Nichols, C. L., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.133 · Cited by 7
Yao, W., Mu, W., Zeifman, A., Lofti, M., Remillard, C. V., Makino, A., Perkins, D. L., Garcia, J. G. N., Yuan, J. X. ‐., & Zhang, W. (2011) · Pulmonary Circulation · doi:10.4103/2045-8932.87310 · Cited by 7
“, abnormal valve cell division) found in patients taking fenfluramine.[12] Particularly, in cells expressing recombinant 5-HT2B receptors, norfenfluramine potently stimulates the hydrolysis of inositol phosphates, increases intracellular Ca2+, and activates the mitogen-activated protein kinase (MAPK) cascade, the latt…”
BackgroundClozapine augmentation with amisulpride
Porcelli, S., Serretti, A., & Bianchini, O. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140094 · Cited by 7
Elenkova, A. P., Atanassova, I., Кirilov, G., Vasilev, V., Kalinov, K., & Zacharieva, S. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0081 · Cited by 8
Antidepressants and Valvular Heart Disease: A Nested Case–Control Study in Taiwan
Lin, C., Hsiao, F., Liu, Y., Gau, S. S., Wang, C., & Shen, L. (2016) · Medicine · doi:10.1097/md.0000000000003172 · Cited by 9
Appiah‐Kubi, P., Olotu, F. A., & Soliman, M. E. S. (2019) · Molecular Informatics · doi:10.1002/minf.201900044 · Cited by 8
Pleuropulmonary Toxicity of Another Anti-Parkinson’s Drug: Cabergoline
Belmonte, Y., de Fàbregues, O., Martí, M. P., & Domingo, C. (2009) · The Open Respiratory Medicine Journal · doi:10.2174/1874306400903010090 · Cited by 7
“The mechanism via which ergoline derivatives produce fibrosis (either pleuropulmonary, retroperitoneal or cardiac) seems to be related to their serotoninergic effect, acting as 5- HT2b receptor agonists [5].”
BackgroundPharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas
Liu, S., Hu, C., Peters, J. B., Tsang, A., Cremers, S., Bies, R. R., & Page‐Wilson, G. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13802 · Cited by 5
Structural diversity in ligand recognition by GPCRs
Jakowiecki, J., Miszta, P., Niewieczerzał, S., & Filipek, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816228-6.00003-9 · Cited by 8
Sakhuja, R., Kondabolu, K., Córdova, T., Travers, S., Vincek, A. S., Kim, M. S., Abboud, K. A., Fang, L., Sun, Z., Canal, C. E., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.060 · Cited by 7
Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population
Lu, C., Chang, C., Yang, Y., Lin, W., & Huang, K. (2018) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2018.07.007 · Cited by 6
The Dark Side of Dopamine Agonist Therapy in Prolactinoma Management
Ananthakrishnan, S. (2017) · AACE Clinical Case Reports · doi:10.4158/ep161709.co · Cited by 6
Design of Monoamine Reuptake Inhibitors: SSRIs, SNRIs and NRIs
Whitlock, G. A., Andrews, M. D., Brown, A. D., Fish, P. V., Stobie, A., & Wakenhut, F. (2008) · Topics in medicinal chemistry · doi:10.1007/7355_2008_028 · Cited by 7
Benfluorex (Mediator®), notre vigilance en question
Frachon, I. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.02.019 · Cited by 6
Pergolide and valvular heart disease: the lower the better?
Droogmans, S., Cosyns, B., & Camp, G. V. (2008) · European Journal of Echocardiography · doi:10.1093/ejechocard/jen202 · Cited by 6
Synthesis and bioactivity of psilocybin analogues containing a stable carbon–phosphorus bond
Vandevelde, M., Simoens, A., Vandekerckhove, B., & Stevens, C. V. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00043a · Cited by 6
Piwnica, D., Pathak, A., Schäfer, G., & Docherty, J. R. (2018) · Drugs in R&D · doi:10.1007/s40268-018-0227-y · Cited by 5
“However, it has been suggested that candidate drug molecules should be screened at 5-HT2B receptors and potent agonists should be avoided, especially for treating non-life-threatening disease and for long-term use since duration of therapy is an important determinant of valvulopathic risk [8, 10].”
Background2023 Julius Axelrod Symposium: Plant-Derived Molecules Acting on G Protein-Coupled Receptors
Labani, N., Gbahou, F., Lian, S., Liu, J., & Jockers, R. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.123.000854 · Cited by 5
Fujioka, K., Malhotra, M., Perdomo, C. A., & Apovian, C. M. (2019) · Obesity Science & Practice · doi:10.1002/osp4.335 · Cited by 4
Chanson, P., & Maiter, D. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00011-1 · Cited by 5
Hemanth, P., Nistala, P., Nguyen, V., Eltit, J. M., Glennon, R. A., & Dukat, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1101290 · Cited by 5
“…1) appear to involve their agonist action at 5-HT2A serotonin receptors (reviewed: Glennon 1996), whereas activation of 5-HT2B receptors can lead to several serious cardiovascular problems (e.g. vavulopathy) (Rothman et al., 2000; Setola et al., 2005; Roth 2007; Elangbam 2010).”
BackgroundAdvances in the Diagnosis, Treatment and Molecular Genetics of Pituitary Adenomas in Childhood
Keil, M. F., & Stratakis, C. A. (2008) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2008.04.02.81 · Cited by 5
Winsky, L., Driscoll, J., & Brady, L. S. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00002-3 · Cited by 6
Endocrine Disorders that Cause Diabetes
Jennings, R. E., & Hanley, N. A. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch20 · Cited by 5
Dopamine agonist withdrawal in hyperprolactinemia: when and how
Salvatori, R. (2017) · Endocrine · doi:10.1007/s12020-017-1469-0 · Cited by 5
Outcomes in surgical management of microprolactinomas: an international multi-institutional series
Golub, D., White, T. G., Shah, H. A., Khaleghi, M., Huntoon, K. M., Zandbergen, I. M., Bakker, L. E. H., Ghalib, L. M., Pelsma, I. C. M., Dowlati, E. P., et al. (2025) · Pituitary · doi:10.1007/s11102-025-01497-1 · Cited by 4
“Serum prolactin levels on postoperative day one (mean 15.6 ± 5.5ng/mL), and at last follow-up (mean 30.3 ± 7.7ng/ mL), were both significantly decreased from immediate after prolonged courses, cabergoline may also increase the risk of developing valvular heart disease [ 23].”
InfluentialSong, Q., Jiang, C., Wang, C., Zhou, L., Han, Z., Sun, N., Huang, P., & Wang, D. (2022) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00788 · Cited by 4
Making Sense of Psychedelics in the CNS
Fordyce, B. A., & Roth, B. L. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae007 · Cited by 4
Self-citationIdentification of tris-(phenylalkyl)amines as new selective h5-HT 2B receptor antagonists
Ponnala, S., Kapadia, N. R., & Harding, W. W. (2014) · MedChemComm · doi:10.1039/c4md00418c · Cited by 4
Advances in medical treatment of Cushing’s disease
Arnaldi, G., Cardinaletti, M., & Boscaro, M. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.6.735 · Cited by 4
Lü, C., Ren, Z., Huan, C., & Cui, G. (2014) · PubMed · Cited by 4
5-HT2B Receptor on Macrophages: What for?
Nieto, C., Rayo, I., & Corbí, A. L. (2021) · The Receptors · doi:10.1007/978-3-030-55920-5_6 · Cited by 4
Carrillo, F., & Mir, P. (2012) · InTech eBooks · doi:10.5772/18648 · Cited by 3
Challenges and controversies in the treatment of prolactinomas
Vroonen, L., Daly, A., & Beckers, A. M. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949239 · Cited by 3
Jang, J. W., Kim, M. S., Cho, Y. S., Cho, A. E., & Pae, A. N. (2012) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2012.06.006 · Cited by 3
Perspective Chapter: The Role of Dopamine Receptors in Neuropsychiatric Diseases
Yaman, B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.112320 · Cited by 4
Chen, V., Altisent, O. A., & Puri, R. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001110 · Cited by 5
“Certain drugs (e.g., fenfluramine-phentermine ergot derivatives) are also associated with organic TR [12].”
BackgroundGračan, R., Blažević, S. A., Brižić, M., & Hranilović, D. (2024) · Biomedicines · doi:10.3390/biomedicines12020357 · Cited by 4
“…detail and are fully understood in the CNS and partially in the digestive tract [21], some side effects (e.g., diabetes, metabolic syndrome, and valvular heart disease [8,22]) reveal that the physiological role of the peripheral serotonergic system is still unclear and needs to be studied further.”
Background3-Substituted 1-methyl-3-benzazepin-2-ones as 5-HT 2C receptor agonists
Shidore, M. M., Machhi, J., Murumkar, P. R., Barmade, M. A., Thanki, J., & Yadav, M. R. (2015) · RSC Advances · doi:10.1039/c5ra17718a · Cited by 3
Predictive Toxicology: Latest Scientific Developments and Their Application in Safety Assessment
Armstrong, D., Li, S., Frieauff, W., Martus, H. ‐., Reilly, J., Mikhailov, D., Whitebread, S., & Urbán, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12367-4 · Cited by 3
Drugs of Abuse Affecting 5-HT2B Receptors
Luethi, D., & Liechti, M. E. (2021) · The Receptors · doi:10.1007/978-3-030-55920-5_16 · Cited by 5
Medical treatment of the motor features of Parkinson disease
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C. L., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00006-8 · Cited by 5
Gollnick, H. P. M. (2009) · Springer eBooks · doi:10.1007/978-3-540-29316-3_110 · Cited by 3
Heterotopic Transcatheter Tricuspid Valve Replacement in a Patient With Carcinoid Heart Disease
Stolz, L., Doldi, P. M., Weckbach, L. T., Schwinger, R. H. G., Stocker, T. J., Maßberg, S., Näbauer, M., & Hausleiter, J. (2022) · JACC Case Reports · doi:10.1016/j.jaccas.2022.10.011 · Cited by 3
Polypharmacology and Adverse Bioactivity Profiles Predict Potential Toxicity and Drug‐Related Adrs
Kaserer, T., Temml, V., & Schuster, D. (2014) · Wiley eBooks · doi:10.1002/9781118783344.ch2 · Cited by 4
Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case–control study
Frishman, W. H. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70228-1 · Cited by 3
The sEROtonergic pathway: a hERO for the brain, a zERO for the valves?
Backer, T. L. M. D., & Timmermans, F. (2019) · Heart · doi:10.1136/heartjnl-2018-314551 · Cited by 2
Korczyn, A. D. (2008) · Elsevier eBooks · doi:10.1016/b978-012373960-5.00028-9 · Cited by 3
Cardiovascular oxidative stress: recent findings on ACE2 And MAO
Silva, R. A. P. (2012) · doi:10.17077/etd.109quuf9 · Cited by 3
Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas
Rudman, Y., & Shimon, I. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102095 · Cited by 2
Anorexigènes et maladies cardiovasculaires : les liaisons dangereuses
Yerly, P., & Vachiéry, J. (2011) · Réanimation · doi:10.1007/s13546-011-0301-8 · Cited by 5
“L’hypothèse actuelle est donc celle d’une activation directe du récepteur 5-HT2B par la norfenfluramine, avec pour conséquence un effet promitogène sur le myofibroblaste et un effet de production de GAG par l’intermédiaire d’une sécrétion de transforming growth factor beta (TGF-β) [49].”
BackgroundUne insuffisance aortique diagnostiquée sous cabergoline
Chague, F., Belleville, I., Boujon, B., & Petit, J. (2008) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2008.05.022 · Cited by 2
Prajapati, N. K., Giridhar, R., Sinha, A., Kanhed, A. M., & Yadav, M. R. (2015) · Molecular Diversity · doi:10.1007/s11030-015-9600-8 · Cited by 2
Groupement automatisé de termes liés aux valvulopathies médicamenteuses dans MedDRA
Asfari, H., Souvignet, J., Louët, A. L., Trombert, B., Jaulent, M., & Cédric Bousquet, B. (2016) · Therapies · doi:10.1016/j.therap.2016.06.003 · Cited by 2
Leblon, T., Riolet, C., Ennezat, P. V., & Maréchaux, S. (2021) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytab516 · Cited by 3
“The appetite suppressant benfluorex activates the serotonin 5HT2B receptor pathway that may lead to cellular proliferation and cardiac valvular fibrosis.(1,9,10) In France, epidemiology studies found”
BackgroundThe Role of Biotransformation Studies in Reducing Drug Attrition
Spracklin, D. K., Kalgutkar, A. S. S., & Nedderman, A. N. R. (2013) · Topics in medicinal chemistry · doi:10.1007/7355_2012_18 · Cited by 2
Miller, K. J., & Azzara, A. V. (2008) · Molecular Interventions · doi:10.1124/mi.8.2.4 · Cited by 2
“Fenfluramine, a stimulator of serotonin release and an inhibitor of serotonin reuptake, was marketed as a weight loss agent from 1973 until 1997 (5), when it and its more potent enantiomer dexfenfluramine were removed from the market because of their cardiac side effects, which were likely due to activity at the 5-HT…”
BackgroundRepublished: Drug-induced valvular heart disease
Cosyns, B., Droogmans, S., Rosenhek, R., & Lancellotti, P. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-302239rep · Cited by 3
“Transforming growth factor-b (TGF-b) receptor activation is also involved in this process (figure 1).(26) Although both fenfluramine and phentermine lack 5-HT2B agonistic properties, the primary metabolite of fenfluramine, norfenfluramine, is a potent 5-HT2B agonist; Norfenfluramine is also a known metabolite of benfl…”
BackgroundSOME ASPECTS OF RHEUMATIC HEART DISEASE PROBLEM
Petrov, V. S. (2013) · I P Pavlov Russian Medical Biological Herald · doi:10.17816/pavlovj2013282-87 · Cited by 2
Palmer, K. D., & Apovian, C. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00022-9 · Cited by 2
Assessing the fidelity of translation of non‐clinical assays: a Pharma perspective
Gintant, G. A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15796 · Cited by 2
“From Figure 3 in Park et al. (2018) and other serotonergic medications [Roth, 2007]), it is prudent to err on the side of caution and favour assays with high sensitivity and lower specificity (tolerant FP findings), expecting that some candidates would be mis-categorized as ‘FPs’ to ensure drug…”
BackgroundCardiovascular Toxicity of Noncardiovascular Drugs
Bajracharya, O., Shankar, P. R., & Jha, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416595-3.00010-4 · Cited by 2
GPCR Antitarget Modeling: Pharmacophore Models to Avoid GPCR‐Mediated Side Effects
Klabunde, T., & Evers, A. (2008) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621460.ch6 · Cited by 3
Therapeutic and Diagnostic Agents for Parkinson's Disease
Booth, R. G., Neumeyer, J. L., & Baldessarini, R. J. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc105.pub2 · Cited by 2
Side Effects of Marketed Drugs: The Utility and Pitfalls of Pharmacovigilance
Whitebread, S., Maciejewski, M., Fekete, A., Lounkine, E., & Urbán, L. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch01 · Cited by 2
Maroteaux, L., Roumier, A., Doly, S., Diaz, S. L., & Belmer, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_286 · Cited by 3
Tepper, S. J., Albrecht, D., & Kellerman, D. (2024) · Cephalalgia Reports · doi:10.1177/25158163241292297 · Cited by 2
“20 Chronic stimulation of the 5-HT 2B receptor has also been implicated as a mechanism for fi brosis, 55 but again this would likely only be a concern in situations where high 8-OH-DHE concentrations are seen, such as chronic oral dosing where fi rst-pass metabolism results in higher metabolite…”
Debate: Surgery as Initial Therapy for Microprolactinoma
Molitch, M. E., & Mamelak, A. N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf434 · Cited by 4
5-HT2B Receptor in Cardiopulmonary Disease
Snider, J. C., & Merryman, W. D. (2021) · The Receptors · doi:10.1007/978-3-030-55920-5_10 · Cited by 1
Feng, C., Liu, R., Brooks, R., Wang, X., Jespers, W., González, M. G., van Westen, G. J. P., Danen, E. H. J., & Heitman, L. H. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177081 · Cited by 1
Vogt, S. B., & Liechti, M. E. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.003 · Cited by 2
Non-clinical cardiovascular safety testing: Current status, gaps and emerging trends
Hoffmann, P., & Pugsley, M. K. (2025) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2025.108403 · Cited by 2
Castle‐Kirszbaum, M., & McCormack, A. I. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102083 · Cited by 1
Le, G. H., Wong, S., Johnson, D. E., Orsini, D. K., Zheng, Y. J., Teopiz, K. M., Dri, C. E., Rosenblat, J. D., & McIntyre, R. S. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70344 · Cited by 1
“44,47 FDA public materials had incorporated this concern by the lorcaserin review process in 2012, wherein reduced 5-HT2B potency was considered reas-suring with respect to off-target valvulopathy risk.”
Medical Imaging in Drug Development
Krasnow, J. S. (2013) · Springer eBooks · doi:10.1007/978-1-84882-710-3_6 · Cited by 1
Barton, J. C., & Elangbam, C. S. (2009) · Journal of Histotechnology · doi:10.1179/014788809794747999 · Cited by 1
Valvular Heart Disease in Patients with Prolactinomas on Cabergoline Treatment
Arrestia, D. (2015) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2015.02.00030 · Cited by 1
“The average cumulative dose of cabergoline was 126 (58-258) mg; mean treatment duration of 53 (26-96) months, similar to the cumulative and duration of treatment dose of our patients.”
Background
Metadata
- Authors
- Roth, B. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Roth, Bryan L.
- ORCID
- Roth, Bryan L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-01-04
- Volume
- 356
- Issue
- 1
- Pages
- 6-9
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1965258805
- Cited by
- 479
- References
- 7
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 11 · 2023: 14 · 2022: 20 · 2021: 18 · 2020: 17 · 2019: 18 · 2018: 20 · 2017: 19 · 2016: 30 · 2015: 29 · 2014: 25 · 2013: 32 · 2012: 28
- FWCI
- 35.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- fenfluramine, dexfenfluramine, valvular heart disease, drug-induced valvular disease, leaflet thickening, echocardiographic findings
- MeSH terms
- Cabergoline, Antiparkinson Agents, Ergolines, Heart Valve Diseases, Humans, Pergolide, Serotonin Receptor Agonists, Dopamine Agonists, Receptor, Serotonin, 5-HT2B, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.